Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intel...

  • 1 year ago

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

PARIS — Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that th...

  • 1 year ago

Find us here